<DOC>
	<DOCNO>NCT02309658</DOCNO>
	<brief_summary>The propose study determine neoadjuvant chemotherapy follow chemoradiation safe effective locally advanced cervical cancer patient . Moreover , study would determine association hENT1 expression response rate gemcitabine .</brief_summary>
	<brief_title>Neoadjuvant Chemotherapy Locally Advanced Cervical Cancer Patients</brief_title>
	<detailed_description>The study develop execute Medicina Integral Prof. Fernando Figueira Institute - IMIP since September/2013 . The primary objective evaluate safety neoadjuvant chemotherapy base gemcitabine follow chemoradiation cervical cancer patient . Data collect medical oncology clinic , patient medical visit receive chemotherapy treatment . New case cervical cancer patient analyse eligibility criterion . When match criterion , protocol explain , participation offer consent form explain , highlight voluntary aspect process . If agreement participation , two consent form provide sign . Patients receive one copy one go his/her medical record . All demographic , social medical data record . Patients consider first visit day sign consent agreement form , also refer radiooncologist visit . Up 30-business day complete staging ( MRI , PET-SCAN , lab ) initiate neoadjuvant chemotherapy . Before day , cycle , patient see medical oncologist nurse , toxicity data collect . Before neoadjuvant chemotherapy , clinical evaluation perform gynecologic oncologist evaluate clinical response . During chemoradiation , patient weekly visit . The treatment complete brachytherapy , 30-days completion , another clinical evaluation do . After 90 day completion treatment , pelvic MRI PET-SCAN repeat consider determine response rate . Biopsies sample collect . The investigator intend perform immunohistochemical analysis end recruitment identify association hENT1 expression outcomes . Information collect principal investigator EXCEL form , medical visit . Toxicity data analyze every 3 month data monitor committee comprise two medical oncologist , one radiooncologist gynecological nurse . All unexpected event relate committee also Research Ethics Committee IMIP . Patients follow 3/3 month . Inconsistent miss data re-checked medical record . This phase IIa study one arm intervention . Since response rate observe phase III study concomitant platin base chemoradiation 85 % average , give response rate use gemcitabin base adjuvant chemotherapy , chemoradiation , 96.5 % , investigator calculate sample size 49 patient . It consider alpha error 5 % 80 % power . Descriptive analysis variable population hold . The normal numerical variable describe mean +/- standard deviation . The non-parametric numeric variable describe median ( interquartile range ) . Categorical data describe percentage total . The progression free survival overall survival obtain Kaplan-Meier method , use computer program Epinfo .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histological confirm diagnostic cervical carcinoma International Federation Gynecology Obstetrics ( FIGO ) stage Ib2 ( &gt; 4cm ) IVa Performance status 02 ( ECOG scale ) Hemoglobin &gt; 10g/dl , neutrophil &gt; 1500 /mm3 , platelet &gt; 100.000/mm3 Creatinine &lt; 1,5 mg/dl Bilirubin total &lt; 1,6 mg/dl liver enzyme ( AST e ALT ) &lt; 2x ( upper limit normal ) Informed consent . Cervical tumor adenocarcinoma , adenosquamous small cell adenocarcinoma histology Distant metastasis include paraortic node Pregnancy breastfeed Previous chemotherapy , radiotherapy uterine surgery Relevant comorbidity prevent chemotherapy use Previous neoplasia , except nonmelanoma skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>cervix neoplasm</keyword>
	<keyword>hENT1 protein , human</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>